Gennova to finish Phase 2 & 3 trials of its mRNA jab by January 2022

The company had submitted the interim Phase-1 clinical trial data to CDSCO, where it tested for safety and immunogenicity.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3pORKVv
via IFTTT